Agios Pharm Cash Flow Conversion Efficiency
Agios Pharm cash flow conversion efficiency. Based on the latest financial reports, Agios Pharm (AGIO) has a cash flow conversion efficiency ratio of -0.056x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-57.31 Million) by net assets ($1.03 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Agios Pharm worth for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Agios Pharm (2011–2025)
Cash flow conversion efficiency of Agios Pharm from 2011 to 2025. This chart illustrates how Agios Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AGIO share price today for real-time trading data and today's change.
Agios Pharm Cash Flow Conversion Ratio Explained
Agios Pharm cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Agios Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Agios Pharm ranked by their cash flow conversion efficiency. Review Agios Pharm free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianma Microelectronics Co Ltd
SHE:000050
|
0.018x |
|
Guangdong Topstar Technology Co Ltd
SHE:300607
|
0.012x |
|
MVV Energie AG
F:MVV1
|
-0.071x |
|
Astronics Corporation
NASDAQ:ATRO
|
0.197x |
|
Test Research Inc
TW:3030
|
0.050x |
|
Karooooo Ltd
NASDAQ:KARO
|
0.148x |
|
Surgery Partners Inc
NASDAQ:SGRY
|
0.024x |
|
Aehr Test Systems
NASDAQ:AEHR
|
0.006x |
Annual Cash Flow Conversion Efficiency for Agios Pharm (2011–2025)
The table below shows the annual cash flow conversion efficiency of Agios Pharm from 2011 to 2025. Also see AGIO total asset value for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.19 Billion | $-372.98 Million | -0.313x | -23.57% |
| 2024-12-31 | $1.54 Billion | $-389.84 Million | -0.253x | +30.70% |
| 2023-12-31 | $811.02 Million | $-296.06 Million | -0.365x | -29.85% |
| 2022-12-31 | $1.10 Billion | $-309.48 Million | -0.281x | +10.83% |
| 2021-12-31 | $1.29 Billion | $-407.32 Million | -0.315x | +56.68% |
| 2020-12-31 | $399.50 Million | $-290.76 Million | -0.728x | -25.78% |
| 2019-12-31 | $640.53 Million | $-370.62 Million | -0.579x | -30.68% |
| 2018-12-31 | $687.54 Million | $-304.42 Million | -0.443x | +41.71% |
| 2017-12-31 | $375.50 Million | $-285.23 Million | -0.760x | -806.36% |
| 2016-12-31 | $358.59 Million | $38.56 Million | 0.108x | +148.23% |
| 2015-12-31 | $345.12 Million | $-76.95 Million | -0.223x | -59.42% |
| 2014-12-31 | $424.37 Million | $-59.35 Million | -0.140x | +67.39% |
| 2013-12-31 | $131.48 Million | $-56.40 Million | -0.429x | +62.00% |
| 2012-12-31 | $43.90 Million | $-49.55 Million | -1.129x | -368.27% |
| 2011-12-31 | $63.14 Million | $-15.22 Million | -0.241x | -- |
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more